about
Osteoporosis in Parkinson's disease.Osteoporosis after stroke: a review of the causes and potential treatments.Possible synergism of physical exercise and ghrelin-agonists in patients with cachexia associated with chronic heart failure.OnabotulinumtoxinA and multiple sclerosis.The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.Neuroprosthetic technologies to augment the impact of neurorehabilitation after spinal cord injury.Biomimetic rehabilitation engineering: the importance of somatosensory feedback for brain-machine interfaces.Technological advances in instrumental assessment in rehabilitation.Instrumental evaluation of gait modifications before and during intrathecal baclofen therapy: a 2-year follow-up case study.Heart Rate Variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: A single blind randomized controlled, crossover pilot study.Electrically Assisted Movement Therapy in Chronic Stroke Patients With Severe Upper Limb Paresis: A Pilot, Single-Blind, Randomized Crossover Study.A multidirectional gravity-assist algorithm that enhances locomotor control in patients with stroke or spinal cord injury.Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study.Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases.A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot.High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis.Targeted neurotechnology restores walking in humans with spinal cord injuryUsing kinematic analysis to evaluate constraint-induced movement therapy in chronic stroke patientsDevelopment and validation of the Italian version of the Spinal Cord Independence Measure IIIGait changes after tendon functional surgery for equinovarus foot in patients with stroke: assessment of temporo-spatial, kinetic, and kinematic parameters in 177 patientsDifferent vitamin D substrate-product relationship after oral vitamin D supplementation in familial benign hypercalcemia, primary hyperparathyroidism, and healthy controlsAcute pseudogout following intravenous neridronate for osteoporosis1α,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cellsCasting, taping or stretching after botulinum toxin type A for spastic equinus foot: a single-blind randomized trial on adult stroke patientsDifferent PTH response to oral peptone load and oral calcium load in patients with normocalcemic primary hyperparathyroidism, primary hyperparathyroidism, and healthy subjectsExtensor hallucis longus transfer as an alternative to split transfer of the tibialis anterior tendon to correct equinovarus foot in hemiplegic patients without overactivity of tibialis anteriorDoes altering inclination alter effectiveness of treadmill training for gait impairment after stroke? A randomized controlled trialGABAergic drug use and global, cognitive, and motor functional outcomes after strokeSafety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity TreatmentAcute pseudogout after cinacalcet treatment
P50
Q34974235-37F75512-88B7-4443-9FAB-FDBE968CBC7DQ37538305-2F730506-5AA6-4FDD-ABB1-C910532076BEQ38172031-E4211CBE-153C-44FA-A795-A3C4809FA8CFQ38222311-F6D2F07A-C622-4D78-86E9-92EB225D4AE0Q38226482-B2DB53E1-77AF-4CB5-8651-34826657A698Q38534713-A010089E-6988-40AB-9E05-22108FDE5A91Q38862885-D88C7170-AE6A-4A6F-80EA-34D1A41B205AQ42029983-A6A3F1AF-A3DB-416E-9E1F-4E5A653398F6Q46399081-F8FF6CB1-A5A7-41FF-8FED-6FCBF7CD7961Q47278061-92A8A4E2-2EA8-45F6-BAC5-DC99B4FB9D31Q47373651-C456AA93-AD58-4AEB-A357-9FE996240CC9Q47759506-E0E7B471-76C4-4B22-9399-915AB7945809Q50927799-811BA5E0-25B0-43E6-93A7-D3ACB9D036DBQ51350551-CE7D0EE4-9438-4B75-80D7-C9356F82B6A9Q51393905-F88B80FD-1B25-42BE-AD59-D9841847DDC9Q51799845-7C0BB38D-BE58-4F9E-ADBF-950F32E4A486Q53594520-FA855E52-B713-4201-9A45-0AFF3E3CE082Q59093325-63D06ED3-095A-44DD-8033-957C89908577Q80535794-3739DAEC-3CE1-425F-96C8-C7EA2906712EQ82781485-1E578BC5-4FB3-4D70-96A3-96E8F544776CQ83289912-83321ABC-0F7A-4951-A656-6F19313ADC04Q83395452-798FDA8B-7D7C-4ED9-B99E-BA4E59BB415BQ84150645-C78992E4-3287-4834-9F2F-A9B4374932DDQ84403320-22627CB6-07B3-411F-B36A-9FBE6A517D32Q84509315-2C707643-EED0-49B3-904D-FD3CAD0367E2Q84749903-8ED66780-921C-42BB-BC0F-403BA82C6674Q84961327-8EC31410-227A-4154-A527-01AA8CCAB108Q87000056-0E040B2D-A408-496B-A707-1EAD57303AFFQ89344084-24CE89DE-EF28-4C4D-80C3-3468B54F49E4Q91413341-6A472C50-0E86-4E83-82EB-6022688CEAB9Q91649061-601945AD-E8BC-42C7-96A4-CF55AB495D67
P50
description
researcher ORCID ID = 0000-0001-7849-1290
@en
wetenschapper
@nl
name
Stefano Carda
@ast
Stefano Carda
@en
Stefano Carda
@es
Stefano Carda
@nl
type
label
Stefano Carda
@ast
Stefano Carda
@en
Stefano Carda
@es
Stefano Carda
@nl
prefLabel
Stefano Carda
@ast
Stefano Carda
@en
Stefano Carda
@es
Stefano Carda
@nl
P106
P1153
8234565500
P21
P31
P4012
P496
0000-0001-7849-1290